In this episode, we hear from Mark Wuttke, CEO of Dopavision. In their own words, Dopavision is pioneering the development of innovative solutions that target the eye’s innate dopamine pathway to address unmet needs in ophthalmology using digitally delivered light.  Topics include: The background to Dopavision The pediatric Myopia vs adult Myopia markets Patient experience using Dopavision Changes to clinical trials and the mechanism of action Plans for commercialization Potential future applications to other ophthalmological conditions and neurological conditions  The future of OTC vs Rx Guest Links and Resources: Connect with Mark Wuttke on LinkedIn Visit Dopavision Listen to Digital Therapeutics for Pediatrics, Oncology and Managing Pain with Francesca Wuttke Episode PDF Host Links: Connect with Eugene Borukhovich: Twitter | LinkedIn Connect with Chandana Fitzgerald, MD: Twitter | LinkedIn Connect with YourCoach.health: Website | Twitter Check out Shot of Digital Health with Eugene and Jim Joyce: Website | Podcast App HealthXL: Website | Twitter | Join an Event Digital Therapeutics Podcast would not be possible without the support of leading DTx organizations. Thank you to: > Presenting Partner: Amalgam Rx > Contributing Partners and Sponsors: LSI | Bayer G4A | Lindus Health Follow Digital Health Today: Browse Episodes | Twitter | LinkedIn | Facebook | Instagram Follow Health Podcast Network: Browse Shows | LinkedIn | Twitter | Facebook | Instagram